Latest Research from Top Endocrine Journals

Emergency Medicine Endocrine Pharmacy/Pharmacology Renal

Lispro vs. Regular Insulin for Hyperkalemia
February 18, 2026February 25, 2026

Spoon Feed —
When comparing IV insulin lispro versus IV insulin regular for hyperkalemia in the ED, lispro was associated with a significant decrease in potassium but an increase in hypoglycemic events.

Source
Comparison of Single-Dose Intravenous Insulin Regular vs. Insulin Lispro for Hyperkalemia Treatment in the Emergency Department: The SIR-LISPRO Trial. Am J Emerg Med. 2025 Dec 26;101:92-98. doi: 10.1016/j.ajem.2025.12.031. Epub ahead of print. PMID: 41477935; PMCID: PMC12810486.

Read More Lispro vs. Regular Insulin for Hyperkalemia
Critical Care Emergency Medicine Endocrine Pediatric Emergency

Does the Two-Bag Method Help with DKA?
October 28, 2025November 1, 2025

Spoon Feed —
The two-bag method of treating DKA was superior for both adult and pediatric patients in this systematic review and meta-analysis.

Source
Two-bag Versus One-bag Method for Adult and Pediatric Diabetic Ketoacidosis Management. Ann Emerg Med. 2025 Sep 6:S0196-0644(25)01095-9. doi: 10.1016/j.annemergmed.2025.07.032. Epub ahead of print. PMID: 40913602.

Read More Does the Two-Bag Method Help with DKA?
Endocrine GI Internal Medicine

MASLD in Diabetes – Screen and Intervene
August 7, 2025August 4, 2025

Spoon Feed —
This American Diabetes Association (ADA) consensus report addresses how to improve screening and early intervention for metabolic-dysfunction-associated steatotic liver disease (MASLD) in patients with prediabetes or type 2 diabetes.

Source
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094. PMID: 40434108

Read More MASLD in Diabetes – Screen and Intervene
Endocrine Internal Medicine

Do GLP-1s Increase Risk of Thyroid Cancer?
August 1, 2025July 29, 2025

Spoon Feed —
Glucagon-like peptide-1 receptor agonists (GLP1 agonists) are not conclusively linked to an increased risk of thyroid cancer in observational trials.

Source
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2025 Jun 4:dc250154. doi: 10.2337/dc25-0154. Epub ahead of print. PMID: 40465422

Read More Do GLP-1s Increase Risk of Thyroid Cancer?
Endocrine GI Internal Medicine

GLP-1s and GI Side Effects
July 31, 2025July 29, 2025

Spoon Feed —
GLP-1 receptor antagonists likely increase the risk of cholelithiasis and GERD when compared to placebo, but this meta-analysis of RCTs suggests that the risk of pancreatitis, cholecystitis, and intestinal obstruction may be lower than previous studies.

Source
Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025 Jun 9:S0016-5085(25)00845-5. doi: 10.1053/j.gastro.2025.06.003. Epub ahead of print. PMID: 40499738

Read More GLP-1s and GI Side Effects
Cardiology Endocrine Internal Medicine

Oral Semaglutide and CV Outcomes in High-Risk DM2
July 30, 2025July 27, 2025

Spoon Feed —
Oral semaglutide decreased major adverse cardiovascular events in patients with diabetes and cardiac comorbidities.

Source
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025 May 29;392(20):2001-2012. doi: 10.1056/NEJMoa2501006. Epub 2025 Mar 29. PMID: 40162642

Read More Oral Semaglutide and CV Outcomes in High-Risk DM2
Endocrine Internal Medicine

Does an Insulin Pump Help in Type 2 Diabetes?
July 3, 2025June 29, 2025

Spoon Feed —
In a 13-week randomized controlled trial (RCT) involving adults with insulin-treated type 2 diabetes (T2DM), automated insulin delivery (AID) was associated with a greater reduction in hemoglobin A1c (HbA1c) than intermittent insulin delivery.

Source
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med. 2025 May 8;392(18):1801-1812. doi: 10.1056/NEJMoa2415948. Epub 2025 Mar 19. PMID: 40105270

Read More Does an Insulin Pump Help in Type 2 Diabetes?
Endocrine Family Medicine Internal Medicine Pharmacy/Pharmacology Preventive Health

Tirzepatide vs. Semaglutide for Treatment of Obesity
June 27, 2025June 20, 2025

Spoon Feed —
For the treatment of obesity in non-diabetic adults, tirzepatide was superior to semaglutide in both body weight reduction (20.2% tirzepatide vs 13.7% semaglutide) and waist circumference.

Source
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 May 11. doi: 10.1056/NEJMoa2416394. Epub ahead of print. PMID: 40353578

Read More Tirzepatide vs. Semaglutide for Treatment of Obesity
Endocrine Family Medicine GI Internal Medicine

Wait, GLP-1 Agonists Might Make Pancreatitis Better?
June 23, 2025July 16, 2025

Spoon Feed —
GLP1 agonist use was associated with better pancreatitis outcomes in a retrospective study of patients with type 2 diabetes.

Source
Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis. Am J Gastroenterol. 2025 May 13. doi: 10.14309/ajg.0000000000003525. Epub ahead of print. PMID: 40358430

Read More Wait, GLP-1 Agonists Might Make Pancreatitis Better?
Endocrine Internal Medicine Landmark Neurology

Do Glucose-Lowering Drugs Impact Cognitive Outcomes?
June 13, 2025June 7, 2025

Spoon Feed —
In the GRADE RCT, poor glycemic control was associated with worse cognitive scores in patients with type 2 diabetes. However, none of the investigated treatments showed a superior effect on cognitive scores, despite insulin glargine and liraglutide offering better glycemic control.

Source
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial. JAMA Intern Med. 2025 May 19:e251189. doi: 10.1001/jamainternmed.2025.1189. Epub ahead of print. PMID: 40388190

Read More Do Glucose-Lowering Drugs Impact Cognitive Outcomes?